Compare MXCT & TTEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | TTEC |
|---|---|---|
| Founded | 1999 | 1982 |
| Country | United States | United States |
| Employees | 91 | 69400 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0M | 128.5M |
| IPO Year | 2021 | 1996 |
| Metric | MXCT | TTEC |
|---|---|---|
| Price | $1.24 | $2.05 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | ★ 932.0K | 602.5K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.80 |
| EPS | ★ N/A | N/A |
| Revenue | $33,026,000.00 | ★ $1,509,171,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.50 | $0.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2.15 |
| 52 Week Low | $0.64 | $1.98 |
| 52 Week High | $2.37 | $5.51 |
| Indicator | MXCT | TTEC |
|---|---|---|
| Relative Strength Index (RSI) | 65.10 | 32.75 |
| Support Level | $0.77 | N/A |
| Resistance Level | $1.30 | $3.88 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 68.00 | 15.26 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
TTEC Holdings Inc provides customer engagement management tools and services. The company operates through two operating segment, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and its revenues are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.